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Correlation between c-myc gene expression and phosphatidylinositol (PI) metabolism was studied using se- 
ven human kidney cancer cell lines. We found that the exceptional incorporation of 32P into CDP-diacyl- 
glycerol (CDP-DG) was observed in only two cell lines, in which c-myc expression was increased among 
seven cell lines tested. In these two cell lines, PI was also labeled. The other five cell lines indicated the accu- 
mulation of radioactive PI, whereas CDP- DG was unlabeled. 
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1. INTRODUCTION 
Recent studies have suggested that several steps 
in the PI cycle may be involved in the action of 
mitogenic signaling [l]. Activation of cellular on- 
cogenes is known to result in cell transformation. 
Here, we attempted to determine whether c-myc 
expression in cell proliferation is related to the PI 
cycle. We have measured levels of c-myc RNA, as 
well as that of PI turnover metabolites, with 7 cell 
lines established from human kidney cancers. 
Among the 7 cell lines, qnly two were found to 
have increased c-myc expression. Furthermore, on- 
ly these two cell lines showed a very marked 
enhancement of 32P labeling in CDP-DC, when 
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these cells were incubated with ‘*Pi. The results 
support the idea that the PI cycle might be 
associated with the activation of c-myc gene ex- 
pression. 
2. MATERIALS AND METHODS 
2.1. Materials 
Carrier-free [32P]orthophosphate (32Pi, 1 mCi/ 
ml) and [32P]dCTP (3000 Ci/mmol) were purchas- 
ed from Amersham. Seven human renal cancer cell 
lines were used in this study. YCR-1 and RC- 
YAMATO cells were established in our laboratory; 
KN-41, 5873T and C-6-3 cells were supplied by 
Kanazawa University (Kanazawa, Japan), Duke 
University (NC, USA) and Osaka Adult Disease 
Center (Osaka), respectively. ACHN and CAKI-2 
were obtained from the American Type Culture 
Collection (ATCC). All of these cell lines were 
established from the tumors of human kidney 
cancer. Human promyelocytic leukemia cell line, 
HL-60 was obtained from the Japanese Cancer 
Research Bank. They were subcultured and main- 
tained with Ham’s F-12 medium (Gibco) sup- 
plemented with 10% fetal calf serum (Hiclone 
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Laboratory, USA). The plasmid containing the 
2nd and 3rd exons of human c-myc was obtained 
from ATCC. 
2.2. Labeling of cells with 32Pi and detection of 
CDP-DG 
Labeling of cells with 32Pi was carried out ac- 
cording to Sugimoto et al. [2]. Subsequent extrac- 
tion and analysis of “P-labeled phospholipids 
were carried out as in [3]. The identity of radio- 
labeled phospholipids was confirmed by co-chro- 
matography with authentic samples. 
2.3. RNA extraction and Northern blotting 
Cytoplasmic RNA was extracted from the 
cultured kidney cancer cell lines using NP-40 as 
described by Lee et al. [4]. 20 ag RNA from each 
cell line was isolated and submitted to the RNA gel 
study. Northern blot experiments were performed 
in the usual manner. 
3. RESULTS 
All cell lines showed typical growth 
characteristics of cancer cells, i.e. anchorage- 
independent growth and loss of contact inhibition. 
The population doubling time of these cells was 
found to be 17.0, 18.0, 20.4, 21.6, 22.0, 31.2, 32.4 
and 38.0 h in KN-41, YCR-1, RC-YAMATO, 
ACHN, 5873T, CAKI-2 and C-6-3 cells, respec- 
tively. Obviously, the first half of the group show 
a shorter population doubling time (about 20 h), 
whereas that of the others is 1 J-times longer (more 
than 30 h). 
As shown in fig.1, c-myc expression was in- 
creased in the two cell lines, YCR-1 and KN41, 
which showed an unusually large amount of ac- 
cumulation of radioactivity in the band of CDP- 
DG. The other cell lines, ACHN, RC-YAMATO, 
CAKI-2, C-6-3 and 5873T, which did not show in- 
creased c-myc expression, indicated no accumula- 
tion of the radioactivity in the position of 
CDP-DG. 
Two-dimensional TLC analysis was also applied 
to 32P-labeled phospholipids and it was found that 
32P incorporation into CDP-DG and PG was in- 
creased markedly in KN41 and YCR-1, after 
60 min incubation with 32Pi, while both CDP-DG 
and PG were unlabeled or weakly labeled in other 
cell lines (fig.2a,b). 
160 
(a1 
1234567 
2.4 kb 
(b) 
CDP-DG - 
1234567 
- PI 
- PIP 
- PIP2 
- Origin 
Fig.1. Comparison between c-myc gene expression and 
the 32P-labeling of phospholipids for 7 kinds of cell 
lines. (a) Autoradiograph of Northern blot with 
cytoplasmic RNA. (b) Autoradiograph of one- 
dimensional HPTLC pattern of 32P-labeled phospho- 
lipids. Lanes: 1, KN-41; 2, YCR-1; 3, ACHN; 4, 5873T; 
5, C-6-3; 6, CAKI-2; 7, RC-YAMATO. 
The rate of “P incorporation into CDP-DG was 
measured at various incubation times, and it was 
found that the rate of radiolabeled CDP-DG ac- 
cumulation in the cell lines, YCR-1 and KN41, was 
greater than that of 32P-labeled PI accumulation in 
other cell lines (fig.2c,d), although the rates of ac- 
cumulation of labelled PIP and PIP2 are almost 
the same for all cell lines tested. These results sug- 
gest that the PI cycle is activated in c-myc ex- 
pressed cell lines. 
We examined c-myc expression and 32P labeling 
of phospholipids in HL-60 leukemia cells for com- 
parison. A significant increase in the level of c-myc 
RNA was evident, but labelled CDP-DG was not 
observed in the cell line (not shown). Other on- 
cogenes, c-fos, c-fms and c-Ha-ras, were found to 
be expressed equally but weakly among the cell 
lines tested. 
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Fig.2. Autoradiograph of two-dimensional TLC pattern 
of 32P-labeled phospholipids for (a) KN-41 and (b) 
5873T cells. Autoradiograph of one-dimensional 
HPTLC patterns of phosphorylated phospholipids for 
various incubation times (10, 20, 40 and 60 min) for 
KN-41 (c) and for 5873T (d). 
4. DISCUSSION 
In this paper, abnormal enhancement of 32P in- 
corporation into CDP-DG has been shown in the 
c-myc expressed human kidney cancer cell lines, 
KN-41 and YCR-1. We have also examined a 
typical c-myc expressed human promyelocytic 
leukemia cell line, HL-60, and have not observed 
increased radiolabeling of CDP-DG. The 
discrepancy in CDP-DG accumulation between 
KN-41 (YCR-1) and HL-60 can be ascribed to the 
difference in genetic characteristics among those 
cell lines tested. The high level of c-myc mRNA in 
HL-60 cells, originating from hematopoietic ells, 
is caused by c-myc gene amplification [5,6]. On the 
other hand, none of the renal cancer cell lines in 
this study showed c-myc gene amplification (not 
shown). Therefore, we prefer to emphasize that ac- 
cumulation of radioactive CDP-DG in c-myc ex- 
pressed cells should be compared among cell lines 
with one kind of tumor, having a very similar 
genetic (and probably metabolic) origin. 
The abnormally increased labeling of CDP-DG 
in kidney cancer cells could be explained as being 
due to the limitation of CDP-DG inositol 
phosphatidyltransferase by the lack of inositol 
substrate as was proposed by Frinkel et al. [7] with 
rat pancreatic islets. Frinkel et al. observed that a 
chronic low level of inositol, brought about by 
glucose stimulation, enhanced the labeling of 
CDP-DG accompanied by that of PG. Hauser and 
Eichberg [8] noted that propranolol caused a 
stimulation in the 32P labeling of PG and CDP-DG 
of isolated rat pineal organ in the absence of 
inositol [S]. Similar results are demonstrated in c- 
myc activated kidney cancer cell line as shown in 
fig.2a. The accumulation of DG was also reported 
in GH3 cells under conditions of chronic low 
inositol [9]. This could explain the activation of the 
c-myc gene, since mitogenes that activate c-myc ex- 
pression also activate PI turnover and increased 
DG concentration [ 10,111. 
Although there are conflicting data [12,13], in- 
tracellular Ca*+ and/or C-kinase might be another 
candidate for the regulation of c-myc activation as 
suggested by Kaibuchi et al. [14]. Further ex- 
periments are necessary to confirm the possibility 
that abnormal PI turnover, as shown in this 
report, might be involved in the activation of the 
c-myc gene. As discussed above, the mechanism 
which activates c-myc transcription is, despite 
many studies, largely unknown, but we suggest 
that it does point to a relationship between c-myc 
activation and the inositide pathway. 
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